Diabetic retinopathy
Conditions
Interventions
non-diabetes, non-retinopathy group:N/A
diabetic non-retinopathy group:N/A
Sponsors
Pearl River Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Control group (CON group, 20 persons) 1) Age over 18 years old; 2) The diagnosis of diabetes was denied by examination, or the volunteers reported that they had no history of diabetes and could provide proof of recent physical examination. 3) There were no obvious manifestations of diabetic retinopathy such as vascular proliferation, sclerosis and hemorrhage by fundus examination. 4) No other underlying diseases may affect the results of this study. 2. The experimental group (including DR group (including PDR group and NPDR group) and DNR group, a total of 80 people) 1) Aged over 18 years. 2) Diabetic patients diagnosed by Endocrinology Department (according to American ADA diagnostic criteria in 2017: HbA1c (> 6.5%); Fasting blood glucose FPG (> 7.0 mmol/L3); 2-hour blood glucose (> 11.1 mmol/L) during oral glucose tolerance test; In the presence of typical hyperglycemia, random blood sugar (> 11.1 mmol/L).
Exclusion criteria
Exclusion criteria: 1) Patients with fundus vascular diseases such as retinal vein occlusion and macular degeneration; 2) Severe ocular trauma patients, such as intraocular foreign body, traumatic retinal detachment, etc. 3) Patients with acute conjunctivitis, keratitis, uveitis, iridocyclitis, endophthalmitis and other eye infections; 4) patients with ocular tumors; 5) Recent (< 4 months) patients taking anti-vascular drugs and anticoagulants; 6) Patients who used prescribed ophthalmic drugs (corticosteroids, vasoactive drugs and non-steroidal anti-inflammatory drugs) orally or locally during the study period and one week before the trial; 7) Patients with systemic diseases, such as hypertension, hyperthyroidism, abnormal coagulation function, rheumatic immune disease, anemia, malignant tumors and other systemic diseases; 8) Women in pregnancy and lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TBIL;DBIL;IBIL;serum lipid;FPG;CREA;HbA1C;Serum magnesium;AGEs;sRAGE;esRAGE;APN;VEGF; | — |
Countries
China
Contacts
Public ContactMin Fu
Ophthalmology Department, Pearl River Hospital
Outcome results
None listed